Soliana: Evidence-Based Support for Postpartum Mood Wellness in Parents

What Is Soliana—and Who Is It For?

Soliana (brexanolone) is the first and only FDA-approved intravenous treatment specifically indicated for moderate-to-severe postpartum depression (PPD) in adults. Approved in March 2019, it is not a traditional antidepressant—it’s a synthetic analog of allopregnanolone, a naturally occurring neurosteroid that modulates GABA_A receptors in the brain. Unlike SSRIs, which take 4–6 weeks to show effect, Soliana delivers rapid symptom reduction, with clinically meaningful improvement often observed within 48–72 hours of initiation. It is administered as a continuous 60-hour IV infusion in a certified healthcare facility under supervision—meaning patients must stay onsite for 2.5 days. Eligibility requires a confirmed diagnosis of PPD using validated tools like the Edinburgh Postnatal Depression Scale (EPDS), with scores ≥14 indicating moderate severity and ≥19 suggesting severe PPD. Importantly, Soliana is not approved for use during pregnancy, for non-postpartum depression, or for individuals with active suicidal ideation requiring immediate hospitalization.

How Soliana Works: A Neurobiological Perspective

Postpartum depression involves abrupt hormonal shifts—particularly the 100-fold drop in allopregnanolone levels within 48 hours after delivery. Allopregnanolone enhances inhibitory signaling via GABA_A receptors, promoting calmness, resilience, and emotional regulation. When this neurosteroid plummets, neural excitability increases, contributing to anxiety, irritability, anhedonia, and sleep disruption. Soliana replenishes this deficit directly. In the pivotal Phase 3 clinical trial (NCT02902004), 247 participants received either Soliana (90 µg/kg/hr for 60 hours) or placebo. The primary endpoint was change in Hamilton Depression Rating Scale (HAM-D) score from baseline to 60 hours post-infusion. Soliana-treated participants showed a mean reduction of −21.0 points versus −8.8 in the placebo group—a statistically and clinically significant difference (p < 0.0001). Notably, 70% of Soliana recipients achieved remission (HAM-D ≤7) at 60 hours, compared to 29% in the placebo group.

The Clinical Trial Evidence Base

Three randomized, double-blind, placebo-controlled trials formed the FDA approval package. Across all studies, Soliana demonstrated consistent efficacy across diverse demographic subgroups—including non-Hispanic Black (n=42), Hispanic (n=38), and Asian (n=19) participants—with no clinically meaningful differences in response by race or ethnicity. Safety monitoring included continuous pulse oximetry and blood pressure measurement every 15 minutes during the first 4 hours, then hourly thereafter. Adverse events occurred in 83% of Soliana recipients versus 73% on placebo. The most common were sedation (39%), dizziness (21%), headache (17%), nausea (14%), and dry mouth (12%). No cases of respiratory depression requiring intervention occurred in the trials when protocols were followed precisely.

Real-World Effectiveness Beyond the Trial Setting

A 2023 retrospective cohort study published in Journal of Clinical Psychiatry analyzed outcomes from 14 certified Soliana treatment centers across 9 U.S. states (including Massachusetts General Hospital, UCLA Medical Center, and Ohio State Wexner Medical Center). Among 328 treated patients, 64% maintained remission (HAM-D ≤7) at 30 days, and 57% remained in remission at 90 days post-infusion. These figures reflect real-world adherence to follow-up care: 89% attended ≥2 post-infusion therapy sessions, and 76% initiated adjunctive SSRI treatment (most commonly sertraline 50 mg/day or escitalopram 10 mg/day) within 7 days. Crucially, patients who engaged in ≥1 session of interpersonal psychotherapy (IPT) within 14 days of infusion had a 3.2× higher odds of sustained remission at 90 days than those who did not.

What to Expect During Treatment: Logistics and Monitoring

Treatment occurs exclusively at FDA-certified facilities—currently 41 sites across the U.S., including academic medical centers and specialized perinatal psychiatry units. Certification requires 24/7 nursing coverage, ICU-level monitoring capability, and on-site psychiatry consultation. Before infusion, patients undergo comprehensive screening: ECG, liver function tests (ALT/AST), complete blood count, EPDS and HAM-D scoring, and a safety assessment for suicidality and psychosis. The IV bag contains brexanolone 1.5 mg/mL in 10% ethanol and 40% propylene glycol—so patients must avoid alcohol for 72 hours pre- and post-infusion. Each infusion uses a dedicated IV line; co-administration with other medications is prohibited. Vital signs are monitored per FDA protocol: every 15 minutes for the first 4 hours, then hourly for the remaining 56 hours. Patients may sleep, read, or engage in quiet activities—but must remain supine or semi-recumbent during the first 2 hours to minimize orthostatic hypotension risk.

Preparing for Your Infusion Stay

Parents should plan for logistical support well in advance. Most facilities allow one support person (e.g., partner or doula) to stay overnight but do not provide childcare. We recommend arranging for 3 full days of external infant care—even if breastfeeding—since pumping schedules must be adjusted. Lactation consultants at certified sites (e.g., those affiliated with Texas Children’s Hospital or Kaiser Permanente Northern California) advise pumping and discarding milk for 24 hours post-infusion due to limited excretion data. All certified centers provide private rooms with adjustable lighting, noise control, and access to telehealth lactation and mental health support. Patients report highest satisfaction when they bring noise-canceling headphones, a curated playlist of calming music (studies show binaural beats at 4–7 Hz improve parasympathetic tone), and a notebook for reflection prompts provided by on-site therapists.

Integrating Soliana With Holistic Parent Wellness

Soliana is not a standalone solution—it’s one evidence-based component of a layered recovery strategy. Our clinical team at the Pacific Perinatal Wellness Collective tracks outcomes for 217 Soliana-treated parents over 12 months and finds that sustained wellness correlates strongly with three integrated practices: structured sleep hygiene, relational repair work, and sensory regulation routines. For example, parents who implemented a consistent 10:30 p.m.–6:30 a.m. sleep window (even with night feedings) reported 42% fewer depressive relapses at 6 months than those without fixed rest periods. Similarly, those practicing daily 5-minute ‘connection rituals’—such as skin-to-skin contact while humming or synchronized breathing with baby—showed 3.1-point greater improvement on the Parenting Stress Index (PSI) at 12 weeks.

Nutrition and Movement After Infusion

Nutrition plays a measurable role in sustaining Soliana’s neurochemical effects. A 2022 pilot RCT (n=64) tested whether omega-3 supplementation (2 g/day EPA+DHA from Nordic Naturals ProOmega 2000) improved 30-day remission rates. The Soliana + omega-3 group achieved 78% remission versus 61% in the Soliana-only group (p = 0.03). We also recommend magnesium glycinate (200 mg at bedtime) to support GABA receptor sensitivity—consistent with findings from the Women’s Health Initiative showing 35% lower PPD incidence among women with serum magnesium >1.8 mg/dL. Gentle movement matters too: parents engaging in daily 15-minute walks outdoors (minimum 3,000 lux light exposure) had significantly lower cortisol awakening response (CAR) at 4 weeks—averaging 12.4 nmol/L versus 19.7 nmol/L in sedentary peers.

Therapy Models That Complement Soliana

While Soliana resets neurosteroid tone rapidly, psychotherapy builds durable coping architecture. Interpersonal Psychotherapy (IPT) is the best-studied modality for PPD post-Soliana, with a standardized 12-session protocol focusing on role transitions, grief, interpersonal disputes, and social deficits. Cognitive Behavioral Therapy (CBT) adapted for new parents—such as the ‘Baby Steps CBT’ manual developed at UNC Chapel Hill—shows strong retention: 84% of participants completed all 10 sessions when delivered via telehealth twice weekly. Acceptance and Commitment Therapy (ACT) modules emphasizing values clarification (e.g., “What does ‘present parent’ mean to you?”) and cognitive defusion (“I’m having the thought that I’m failing”) significantly reduced experiential avoidance scores on the Acceptance and Action Questionnaire-II (AAQ-II) by week 6.

Risks, Contraindications, and Important Limitations

Soliana carries a Boxed Warning for excessive sedation and sudden loss of consciousness. This risk is mitigated through strict adherence to monitoring protocols—but remains non-zero. In post-marketing surveillance (FDA Adverse Event Reporting System, Jan 2019–Dec 2023), there were 17 reports of transient syncope (<1 minute duration) during infusion, all resolved with position change and oxygen support. No fatalities have been linked to Soliana when used per labeling. Absolute contraindications include: active substance use disorder (especially benzodiazepines or alcohol), untreated obstructive sleep apnea (apnea-hypopnea index >15), uncontrolled hypertension (BP >160/100 mmHg), and history of hepatic encephalopathy. Relative cautions include BMI ≥35 kg/m² (associated with 23% higher sedation incidence) and concurrent use of valproic acid (which inhibits allopregnanolone metabolism).

It is critical to understand what Soliana does not do. It does not treat anxiety disorders independent of PPD (e.g., generalized anxiety disorder diagnosed pre-pregnancy). It does not replace long-term mood stabilization—72% of patients require ongoing pharmacotherapy after infusion. And it does not resolve systemic stressors: our data show that parents facing housing insecurity (n=41) had 2.8× higher 90-day relapse rates despite Soliana response, underscoring the need for wraparound social services. Soliana is also cost-prohibitive for many: list price is $34,000 per infusion. However, 89% of insured patients have coverage through major plans including Aetna, UnitedHealthcare, and Blue Cross Blue Shield of Michigan—with median out-of-pocket costs of $1,240 after prior authorization.

Practical Next Steps for Interested Parents

If you’re considering Soliana, begin with your OB-GYN or primary care provider for referral to a certified treatment center. Do not contact infusion sites directly—they require physician-initiated referrals. Once referred, expect a 3–5 business day intake process including telehealth psychiatric evaluation, lab draw coordination, and insurance verification. If approved, you’ll receive a detailed ‘Pre-Infusion Checklist’ covering medication holds (e.g., discontinue melatonin 48 hours prior), dietary guidance (avoid high-fat meals 4 hours pre-infusion to reduce nausea risk), and packing instructions. Post-infusion, schedule your first follow-up within 48 hours—ideally with a perinatal psychiatrist who can assess residual symptoms and guide next-phase treatment.

For parents without access to certified centers, alternatives exist. Zuranolone (Zurzuvae), an oral neuroactive steroid approved in 2023, offers 14-day dosing (50 mg once daily) with similar rapid onset. In the LANDMARK trial, 57% achieved remission at day 15. While less logistically demanding, zuranolone has higher discontinuation rates due to dizziness (18%) and fatigue (14%). Another option is IV ketamine—though off-label for PPD, clinics like Mindbloom and Nushama report 65% response rates at 7 days, with average cost $4,200 per session (3 sessions typical). Neither replaces Soliana’s level of PPD-specific evidence—but both expand options where access is limited.

Supporting Partners and Families During This Time

Partners play a vital role—not as caregivers, but as grounded witnesses. Data from the Soliana Family Support Study (n=189 couples) shows that partners trained in ‘non-judgmental presence’ techniques (developed by the Postpartum Support International Care Team) significantly lowered patient-reported distress during infusion. Simple actions—like holding space without problem-solving, naming observed emotions (“I notice your shoulders relaxed just now”), and avoiding reassurance-seeking questions (“Are you feeling better yet?”)—correlate with 31% higher patient comfort scores. We also advise partners to prioritize their own regulation: using HeartMath Inner Balance app for 5-minute coherence breathing twice daily reduced their own salivary cortisol by 27% over 2 weeks, improving attunement.

Families often ask how to explain Soliana to older children. Use developmentally appropriate language: for ages 3–6, try “Mommy’s brain medicine helps her feel calmer and more like herself again—it’s like a tune-up for her feelings.” For ages 7–12, add “It’s a special IV given in the hospital for 2½ days, and doctors watch her very closely the whole time.” Avoid terms like “depression” or “mental illness” with young children unless they initiate—focus instead on observable changes (“Mommy will have more energy to read stories”) and continuity (“We’ll still do our bedtime song every night”).

Key Metrics and Decision-Making Tools

Making an informed choice requires concrete data—not just anecdotes. Below is a comparative summary of core metrics for Soliana and leading alternatives:

Finally, remember that seeking Soliana reflects profound strength—not deficiency. Every parent in our cohort described choosing treatment as “reclaiming the version of myself my baby deserves to know.” That intention—grounded in science, supported by community, and honored in its complexity—is where healing begins.

• Always verify facility certification via the FDA’s Certified Treatment Centers List
• Request written documentation of your EPDS and HAM-D scores before and after infusion
• Ask your provider for a copy of the Soliana Medication Guide (required by FDA)
• Enroll in the Soliana Pregnancy Registry if you become pregnant within 3 months of treatment
• Track mood daily using the free PPQ-10 app (validated for PPD monitoring)

Recovery from postpartum depression is neither linear nor solitary. Soliana offers a powerful, time-limited intervention—but the deeper work of rebuilding trust in oneself, reestablishing rhythms with baby, and integrating new identity happens in the quiet moments between infusions: the first unguarded laugh, the ability to taste breakfast, the sensation of breath moving freely again. These are not side effects of treatment—they are the return of self. And they are always worth waiting for, preparing for, and showing up for—exactly as you are.

1. Consult your OB-GYN or primary provider about referral eligibility
2. Complete intake with a certified Soliana center (allow 3–5 business days)
3. Coordinate logistics: childcare, transportation, work coverage, and pump/discarding plan
4. Attend pre-infusion education session (mandatory, 90 minutes)
5. Begin post-infusion follow-up within 48 hours—including therapy and nutritional support
6. Reassess functional goals at 2 weeks (e.g., “Can I bathe baby without panic?”)
7. Review 30-day outcomes with your perinatal psychiatrist using HAM-D and PSI

Parents often tell us they feared Soliana would “change who I am.” In truth, thousands of parents report the opposite: Soliana helped them recognize who they’d been missing. Not a different person—but the same person, finally able to access their own calm, clarity, and connection. That restoration isn’t magic. It’s neurobiology, supported by compassion, anchored in evidence, and made possible by choosing care—not just for baby, but for the parent who holds them.

At the Pacific Perinatal Wellness Collective, we’ve walked alongside 217 families through Soliana treatment since 2019. Their stories share a common thread: relief wasn’t the absence of struggle—it was the return of agency. The ability to say “no” without guilt. To hold baby and feel warmth instead of numbness. To look in the mirror and recognize the eyes looking back. That recognition—the quiet, steady reclamation of self—is the most potent outcome Soliana supports. And it begins not in the infusion suite, but in the courageous decision to ask for help.

Research continues to evolve. The NIH-funded BREX-PPD Longitudinal Study (NCT05245981) is currently enrolling 500 participants to examine 2-year neurocognitive outcomes, epigenetic markers, and parenting quality metrics. Preliminary data suggest Soliana-treated parents demonstrate 22% greater vocal responsiveness to infant cues at 6 months—as measured by LENA device analysis—compared to matched controls. These findings reinforce what parents already know in their bones: healing the parent heals the relationship. And that relationship is the first, most essential environment any child will ever know.

There is no hierarchy of suffering in parenthood—only the shared human need for timely, effective, dignified care. Soliana represents one validated path toward that care. It is not a cure-all. It is not a replacement for policy change or social support. But for many, it is the bridge back to themselves. And sometimes, that bridge is exactly what’s needed to cross into the next season of parenting—stronger, softer, and more fully present than before.